BIG pharmaceutical companies have often been accused of “extending” their drug patents for as long as possible, depriving many patients of cheaper generic versions of drugs that could potentially save their lives or improve their conditions.
Called evergreening, NGOs had said these companies tend to “extend” drug patent just before the 20-year expiry period by making only a slight modification.
